Plate Nº 42 · recorded October 30, 2026

Health & Medicine ResearchReported finding

New Immunotherapy Drug Shrinks Tumors in 15% of Hard-to-Treat Cases

Invikafusp, a first-in-class dual T-cell agonist, controlled disease in 59.3% of patients with advanced solid tumors resistant to existing immunotherapies, researchers report in Nature Medicine.

By Elena Vasquez4 min read701 words

In brief

  1. Disease control rate was 59.3% at optimal doses, with meaningful tumor shrinkage in 15% of patients
  2. The phase 1 trial tested 34 patients with advanced solid tumors; 18 more enrolled in phase 2
  3. Findings published in Nature Medicine and presented at the ESMO Congress 2026
  4. Invikafusp selectively expands Vβ6/Vβ10 T cells known to infiltrate tumors
Novel cancer immunotherapy drug generates promising clinical trial results - Mass General Brigham
Plate Nº 42Novel cancer immunotherapy drug generates promising clinical trial results - Mass General Brigham — DarkoStojanovic / pixabay

A new immunotherapy drug controlled disease in 59.3% of patients with advanced, treatment-resistant solid tumors, according to first-in-human trial results published in Nature Medicine and presented simultaneously at the ESMO Congress 2026.

The drug, called invikafusp, also produced meaningful tumor shrinkage in 15% of patients who had run out of standard options. Researchers at the Mass General Brigham Cancer Institute co-led the trial, known as START-001, alongside scientists from the National Cancer Institute and Memorial Sloan Kettering Cancer Center.

That response rate may sound modest. For this population, it matters — these were patients whose cancers had already resisted existing therapies.

Why do current immunotherapies fall short?

Immunotherapy drugs work by boosting the body's immune response against cancer cells, and they have improved survival across several tumor types. But only a minority of patients get long-term benefits. Cancers often develop resistance, and current agents can stimulate T cells and other immune mediators indiscriminately, triggering serious side effects.

A more selective drug could fix both problems at once. That's the design logic behind invikafusp.

How does invikafusp work?

Invikafusp binds to two receptors at once — the T-cell receptor and the interleukin-2 receptor — on a specific subset of immune cells called Vβ6/Vβ10 T cells. These cells are known to infiltrate tumors and carry anti-tumor activity.

The double binding matters. By latching onto both receptors cooperatively, the drug promotes expansion of only these particular T cells while leaving other immune cells untouched. In plain terms: it targets the immune soldiers already inside tumors, without activating the ones that cause collateral damage.

Trial data confirmed this selectivity in patients. Invikafusp expanded circulating and intratumoral Vβ6/Vβ10 T cells potently, with the effect peaking at optimal doses.

"There have been many attempts to extend the promise of immunotherapy to more patients. The development of invikafusp was launched in this spirit," said co-lead author Ryan J. Sullivan, MD, a physician-scientist at the Mass General Brigham Cancer Institute. "When we saw the initial data from laboratory experiments, there was a lot of excitement about the promise of this therapy."

What did the trial show?

The trial unfolded in two stages, sponsored by Marengo Therapeutics, the company developing the drug:

  • Phase 1: 34 patients with advanced solid tumors and few remaining treatment options received escalating doses. The drug was well tolerated.
  • Phase 2: 18 additional patients enrolled at optimal doses. Side effects were mostly mild to moderate.
  • Efficacy: Disease control — defined as tumors shrinking or remaining stable — reached 59.3% at optimal doses, with meaningful shrinkage in 15% of patients.

The disease control figure includes stable disease, not just shrinkage, so it should be read carefully. Still, for a first-in-human study in heavily pretreated patients, researchers view the safety profile and selectivity as the headline results.

Who ran the study?

Co-first authors were Ryan J. Sullivan of Mass General Brigham, Nicholas P. Tschernia of the National Cancer Institute, and Claire F. Friedman of Memorial Sloan Kettering Cancer Center. Lillian L. Siu of Princess Margaret Cancer Centre and James L. Gulley of the National Cancer Institute served as co-senior authors.

Funding came in part from Marengo Therapeutics and the NIH's Intramural Research Program of the National Cancer Institute's Center for Cancer Research (ZIA BC 010666). Several study authors are Marengo employees, and Sullivan has received institutional research funding from multiple companies including Marengo, Merck, Novartis and Pfizer, and has consulted for Marengo and others — disclosures worth weighing when industry sponsors fund trials of their own drugs.

What comes next?

The findings are early-phase and preliminary. The sample is small — 52 patients total across both phases — and the trial wasn't designed to prove survival benefits. Researchers don't yet know which patients will respond best.

"There are certainly more studies to complete to understand which patients should be treated with invikafusp, but the initial findings support the continued study of this promising drug," Sullivan said.

The bottom line: invikafusp is a precisely targeted immunotherapy that showed real signals of activity and manageable side effects in patients with few alternatives. Larger trials will decide whether it becomes a standard tool.

via Google News: Clinical Trials (Source)

Filed under

  • invikafusp
  • immunotherapy
  • solid-tumors
  • clinical-trials
  • t-cells
Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Correspondent covering money, funding and market shifts around general science news at SciBeat.

503 articles

Nearby plates

« Previous articleNext article »